ÖÐÊàÉñ¾ÏµÍ³µÄ·¢ÓýºÍѧϰÓÕµ¼µÄÉñ¾»·Â·Öع¹¶¼Êܵ½»ùÒò±í´ïµÄʱ¿Õµ÷¿Ø¡£¡£¡£¡£¡£×éÂѰ×ÖØ¹¹ÔÚÐÄÀíºÍ²¡ÀíÌõ¼þϵ÷¿ØÕâÀà»ùÒòµÄ±í´ïÆð×ÅÖ÷Òª×÷Ó㬣¬Òò´Ë£¬£¬×éÂѰ×ÖØ¹¹¿ÉÄܳÉΪÐí¶àÖØ´óÄÔ¼²²¡µÄDZÔÚÒ©Îï°Ðµã¡£¡£¡£¡£¡£
×éÂѰ׼׻ù×ªÒÆÃ¸±»È·ÒÔΪÐí¶àÉñ¾·¢ÓýÕϰµÄΣº¦»ùÒò¡£¡£¡£¡£¡£Ash1lÊÇÒ»ÖÖ×éÂѰ׼׻ù×ªÒÆÃ¸£¬£¬ÊôÓÚÈýÐØ¼Ò×壨trxG£©ÂѰ׵ijÉÔ±Ö®Ò»£¬£¬ÆäÄÜÞ׿¹¶àÊáÂѰ׼Ò×å¶Ô»ùÒòת¼µÄÒÖÖÆ¹¦Ð§¡£¡£¡£¡£¡£ÏÖÔÚÔ½À´Ô½¶àµÄÑо¿Ö¤Êµ£¬£¬Ash1l»ùÒò¹¦Ð§È±Ê§ÊÇ×Ô±ÕÖ¢Æ×ϵÕϰ£¨autism spectrum disorder, ASD£©±¬·¢µÄÖ÷ҪΣÏÕÒòËØ£¬£¬È»¶ø£¬£¬¹ØÓÚAsh1lµ¥±¶Ìåȱ·¦µ¼ÖÂÓë ASDÏà¹ØÖ²¡»úÖÆÉв»ÇåÎú¡£¡£¡£¡£¡£
2022Äê1ÔÂ26ÈÕ£¬£¬ÉϺ£¿£¿£¿£¿£¿£¿Æ¼¼´óѧÉúÃü¿ÆÑ§ÓëÊÖÒÕѧԺ¹Ü¼ªËɽÌÊÚÍŶÓʹÓÃAsh1lȱʧСÊóÄ£×Ó¡¢ÐÐΪѧ·¶Ê½¡¢¹âÒÅ´«Ñ§µÈ¶à¸öÊÖÒÕÊֶη¢Ã÷Ash1lµ¥±¶Ìåȱ·¦µ¼ÖÂСÊóASDÑùÐÐΪ£¬£¬ÆÆËðÔ˶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ôÀú³Ì£¬£¬²¢¶Ô¸ÃÕ÷Ïó¾ÙÐÐÁËϵͳÐÔ̽Ë÷£¬£¬Ïà¹ØÑо¿Ð§¹û¿¯·¢ÔÚÉñ¾¿ÆÑ§ÆÚ¿¯NeuronÉÏ£¬£¬ÎÊÌâΪASH1L haploinsufficiency results in autistic-like phenotypes in mice and links Eph receptor gene to autism spectrum disorder
Ч¹û
ǰÄÔÉñ¾ÔªAsh1lµ¥±¶Ìåȱ·¦µ¼ÖÂСÊóµÄASDÑù±íÐÍ
Ê×ÏÈ£¬£¬×÷Õß½ÏÁ¿ÁËAsh1l+/-СÊó[1,2]ºÍWTСÊóµÄÐÐΪѧ±íÐÍ£¬£¬ÔÚAsh1l+/-СÊóÖмì²âµ½Á˵¥±¶Ìåȱ·¦£¬£¬Í¬Ê±£¬£¬¿õ³¡ÊµÑ飨the open-field test£©ºÍÂñÖéʵÑ飨the marble-burying test£©ÐÐΪѧ·¶Ê½Ð§¹ûÏÔʾ£¬£¬Ash1l+/-СÊóÌåÏÖÀàËÆ½¹ÂÇ¡¢Öظ´¿Ì°åµÄÐÐΪ£¨Í¼1A,B£©¡£¡£¡£¡£¡£±ðµÄ£¬£¬¶Ô³öÉúºó7-9Ì죨P7-P9£©Ð¡Êó¾ÙÐÐÓ×Êó³¬Éù·¢Éù²âÊÔ£¬£¬·¢Ã÷Ash1l+/-СÊóÔÚÉúÃüÔçÆÚ±£´æÏÖÏàͬÕϰµÄÕ÷Ïó£¨Í¼1C£©¡£¡£¡£¡£¡£ÈýÏäÉ罻ʵÑ飨three-chamber assay£©Ð§¹ûÏÔʾAsh1l+/-СÊóÒ²ÌåÏÖ³öÉç½»Õϰ£¨Í¼1D£©¡£¡£¡£¡£¡£ÕâЩЧ¹ûÌáÐÑÁËAsh1lÍ»±äСÊóÌåÏÖ³öµä·¶µÄ×Ô±ÕÖ¢ÑùÐÐΪ£¬£¬°üÀ¨ÏàͬÄÑÌ⣬£¬Öظ´¿Ì°åÐÐΪ¡¢Éç½»ÕϰµÈ¡£¡£¡£¡£¡£
µ¥Ï¸°û»ùÒò±í´ïÆÊÎö·¢Ã÷£¬£¬ÔÚÖÐÊàÉñ¾ÏµÍ³ÖУ¬£¬ Ash1lÓÅÏÈÔÚÉñ¾ÔªÖбí´ï£¨Í¼1E£©¡£¡£¡£¡£¡£Òò´Ë£¬£¬Ñо¿Ö°Ô±½èÖúÔλÔÓ½»Á´Ê½·´Ó¦£¨HCR-FISH£©×ö½øÒ»²½ÑéÖ¤£¬£¬·¢Ã÷ÔÚÆ¤²ãÉñ¾ÔªÖУ¬£¬Ash1lÑôÐÔÐźÅÓëMap2ÑôÐÔÐźţ¨(Map2+£¬£¬Éñ¾Ôª±ê¼ÇÎ¸ß¶ÈÖØµþ£¨Í¼1F£©£»£»£»£»ÔÚMap2-ϸ°ûÖУ¬£¬Ash1lÐźŵãÊýÄ¿ÏÔ×ÅïÔÌ¡£¡£¡£¡£¡£ÕâÌáÐÑÁËÉñ¾ÔªÖÐAsh1l¹¦Ð§È±Ê§¿ÉÄܵ¼ÖÂ×Ô±ÕÖ¢Æ×ϵÕϰ (Autism Spectrum Disorder, ASD£©ÑùÐÐΪ¡£¡£¡£¡£¡£
»ùÓÚÉÏÊöЧ¹û£¬£¬×÷Õß¹¹½¨Ash1lEmx1-cKOСÊó£¨ÌØÒìÐÔÔÚǰÄÔ£¬£¬ÌØÊâÊÇÐÂÆ¤²ãºÍº£ÂíÇøÇóýAsh1l,ͼ1G-I£©£¬£¬²¢Í¨¹ýÐÐΪѧ·¶Ê½·¢Ã÷£¬£¬Ç°ÄÔAsh1lµ¥±¶Ìåȱ·¦µ¼ÖÂСÊóASDÑùÐÐΪ£¨Í¼1J-L£©¡£¡£¡£¡£¡£
ͼ1 Ash1lµ¥±¶Ìåȱ·¦µ¼ÖÂСÊóµÄASDÑù±íÐÍ
Ash1lÍ»±äСÊó±£´æÇø·ÖÄÜÁ¦È±ÏÝ
½ÓÏÂÀ´£¬£¬Ñо¿Ö°Ô±¶ÔAsh1lȱʧСÊóµÄѧϰÐÐΪ¾ÙÐÐÆÀ¹À£¬£¬½èÖúÌõ¼þÐԿ־巴É䷶ʽ·¢Ã÷£¬£¬Ash1l+/-СÊóºÍWTСÊó¾ùѧ»áÁËÇé¾³ÐÔ¿Ö¾åÌõ¼þ·´É䣬£¬²¢ÌåÏÖ³öÀàËÆµÄ¿Ö¾åÓ°ÏóÖØÌáˮƽ£¬£¬È»¶øAsh1l+/-СÊóÔÚ¿Ö¾åѧϰµÄµÚÈýÌìÌåÏÖ³öľ½©ÐÐΪ£¨freezing, ÀÏÊóµÄÒ»ÖÖ·ÀÓù·´Ó¦£©Ï½µ£»£»£»£»±ðµÄ£¬£¬ÔÚAsh1l+/-СÊóÖÐδÊӲ쵽Á½ÖÖ²î±ðÇéÐÎÏµÄľ½©ÐÐΪ²î±ð£¨WTСÊóÔÚcontext AÖÐÌåÏÖ³ö½Ï¸ßµÄľ½©ÐÐΪ£¬£¬ÔÚcontext B£¨ÐÂÇéÐΣ©ÖÐÌåÏÖ³ö½ÏµÍµÄľ½©ÐÐΪ£©£¬£¬ÌáÐÑÁËAsh1l+/-СÊóÇø·ÖÄÜÁ¦ÊÜËð£¨Í¼2A,B£©¡£¡£¡£¡£¡£
ÔÚÒôµ÷ÒÀÀµµÄÇø·Ö·¶Ê½£¨Í¼2C-E£©ºÍ»ùÓÚÒôµ÷µÄGo-No-goÐÐΪ·¶Ê½£¨Í¼2F-H£©ÖУ¬£¬Ash1l+/-СÊóͬÑùÌåÏÖ³öÏÔ×ŵÄÌý¾õÇø·ÖÕϰ£¨Ìý¾õÄԸɷ´Ó¦£¨ABR£©²âÊÔAsh1l+/-СÊóÎÞÏÔ×ŵÄÌýÁ¦Ëðʧ£©¡£¡£¡£¡£¡£
ΪÁËÑé֤ǰÄÔÉñ¾ÔªÖÐAsh1lȱʧÊÇ·ñ»áµ¼ÖÂÓëAsh1l+/-СÊóÀàËÆµÄÇø·ÖÄÜÁ¦ÕϰÕ÷Ï󣬣¬×÷Õß½èÖúAsh1lEmx1-cKOСÊó¾ÙÐÐÏà¹ØÐÐΪѧ·¶Ê½£¬£¬·¢Ã÷Ash1lEmx1-cKOСÊóÓë¿Ö¾åÓ°ÏóÏà¹ØµÄÌý¾õÇø·ÖÄÜÁ¦ÏÔ×ÅÊÜËð£¨Í¼2J,K£©¡£¡£¡£¡£¡£ÕâÖÖAsh1lÍ»±äСÊóµÄÇø·ÖÄÜÁ¦Òì³£Çкϲ¿·ÖASD»¼ÕßµÄÁÙ´²ÌåÏÖ¡£¡£¡£¡£¡£Ç°ÄÔAsh1lȱʧ¿Éµ¼ÖÂÍ»´¥ºÍÉñ¾»·Â·¹¦Ð§Õϰ£¬£¬ÒÔ¼°Çø·ÖÐÐΪÕϰ¡£¡£¡£¡£¡£
ͼ2 Ash1l+/-СÊóÌåÏÖ³öÕý³£µÄѧϰÄÜÁ¦£¬£¬µ«Çø·ÖÄÜÁ¦ÊÜËð
Ash1lÒÔϸ°û×ÔÖ÷ЧӦµÄ·½·¨½éµ¼Ô˶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ôÀú³Ì
Ëæºó£¬£¬×÷Õß½èÖú¸ß¶û»ùȾɫ·¢Ã÷£¬£¬1ÔÂÁäµÄAsh1l+/-СÊ󯤲ãÉñ¾ÔªºÍ±³²àÎÆ×´ÌåÖм¬Éñ¾Ôª£¨MSNs£©µÄÊ÷Í»¼¬ÃܶÈÏÔÖøÔöÌí£¨Í¼3A£©£¬£¬ÎªÑо¿ÕâÖÖÕ÷ÏóÊÇ·ñÔ´ÓÚÍ»´¥Ïû³ýÀú³Ì£¨synapse elimination£©µÄïÔÌ£¬£¬Ñо¿Ö°Ô±Ñо¿ÁËAsh1+/-СÊóÔ´úƤ²ãÉñ¾ÔªµÄÍ»´¥ÃܶÈת±ä¡£¡£¡£¡£¡£Óñí´ïChR2¹âÃôÂѰ׵ÄÂý²¡¶¾ÔØÌ壨Lenti-CaMKIIa-ChR2£©Ñ¬È¾×÷ÓýµÄÉñ¾Ôª£¬£¬²¢ÓÃLED´Ì¼¤£¨Í¼3B£©£¬£¬·¢Ã÷WTÉñ¾ÔªÔÚLED´Ì¼¤ºó24hÊ÷ͻͻ´¥ËØ£¨SYP£©ÃܶÈÏÔÖø½µµÍ£¬£¬¶øAsh1l+/-×éÔòδÊӲ쵽ÕâÖÖÕ÷Ïó£¨Í¼3C,D£©£¬£¬ÌáÐÑÁËAsh1l¿ÉÄܽ鵼ÁËÔ˶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ôÀú³Ì¡£¡£¡£¡£¡£»£»£»£»îÌå³ÉÏñЧ¹ûÏÔʾ£¬£¬Ash1l+/-×é×÷ÓýµÄÉñ¾ÔªÖУ¬£¬»îÐÔÒÀÀµµÄÍ»´¥Ïû³ýÀú³Ì±»Ï÷Èõ¡£¡£¡£¡£¡£
±ðµÄ£¬£¬×÷Õß»¹Ñо¿ÁËÔÚСÊóÐÂÆ¤²ãÖлîÐÔÒÀÀµµÄÍ»´¥Ïû³ý£¬£¬×·×ÙÁËÌý¾õƤ²ã£¨auditory cortex, AUD£©µ½ºó¶¥Ò¶Æ¤²ã£¨posterior parietal cortex, PTLp£©³¤¾àÀëͶÉäÖáÍ»µÄת±ä¡£¡£¡£¡£¡£Ñо¿Ö°Ô±½«AAV-EF1a-DIO-EYFP×¢ÉäÔÚRbp4-CreСÊóAUD£¬£¬ÌØÒìÐÔ±ê¼ÇÌý¾õƤ²ãL5Éñ¾Ôª£¨Í¼3H£©¡£¡£¡£¡£¡£Ð¡Êó½ÓÊÜÒôµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þѵÁ·£¬£¬³ÉÏñÊÓ²ìÖáͻת±ä·¢Ã÷£¬£¬Éùµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þѧϰ24hºó£¬£¬Ash1l+/-::Rbp4-CreСÊó“bouton”£¨Í»´¥Ð¡½á£©µÄɨ³ýÏÔ×ŵÍÓÚWTСÊ󣬣¬¶ø“bouton”ÐγÉÔò¼á³ÖÎȹ̣¨Í¼3H-J£©¡£¡£¡£¡£¡£
Ϊ̽ÌÖÕâÖÖ“Í»´¥ÐÞ¼ô”Àú³ÌµÄȱʧÊÇ·ñÓÉAsh1lȱʧÉñ¾ÔªµÄϸ°û×ÔÖ÷ЧӦµ¼Öµģ¬£¬Ñо¿Ö°Ô±½«AAV-hSyn-CreºÍAAV-EF1a-DIO-EYFP×¢ÉäÓÚAsh1lfl/flСÊóÓÒ²àAUDÇø£¨Í¼3K£©£¬£¬¶ÔСÊó¾ÙÐÐÒôµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þÐÐΪѧ·¶Ê½ÑµÁ·£¬£¬ÔÚѧϰ֮ºó½èÖúÌåÄÚ³ÉÏñÊÖÒÕ×·×ÙÍ»´¥µÄת±ä£¬£¬·¢Ã÷Ash1lȱʧµÄÉñ¾ÔªÖÐѧϰÒÀÀµµÄÍ»´¥µÄÔöÌíÊýĿûÓб¬·¢¸Ä±ä£¬£¬¶øÑ§Ï°ÓÕ·¢µÄÍ»´¥µÄïÔÌÊýÄ¿ÏÔÖøµÍÓÚÕý³£Ð¡Êó£¨Í¼3K-M£©¡£¡£¡£¡£¡£ÕâЩÊý¾ÝÌáÐÑÁËAsh1lÒÔϸ°û×ÔÖ÷ЧӦµÄ·½·¨½éµ¼Æ¤²ãÉñ¾ÔªµÄÔ˶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ôÀú³Ì¡£¡£¡£¡£¡£
ͼ3 Ash1lÒÔϸ°û×ÔÖ÷ЧӦµÄ·½·¨½éµ¼Ô˶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ôÀú³Ì
Ash1lµ÷¿ØÓ×ÊóºÍ³ÉÄêСÊóÖÐEphA7µÄ±í´ï
½ÓÏÂÀ´£¬£¬×÷ÕßÑо¿ÁËÆä·Ö×Ó»úÖÆ£¬£¬Í¨¹ý¶Ôת¼×éÆÊÎö¼°»ùÒò±¾ÌåÂÛ£¨GO£©ÆÊÎö·¢Ã÷£¬£¬EphÊÜÌåEphA7ÔÚÌý¾õƤ²ãºÍ±³²àÎÆ×´ÌåÖеıí´ï¾ùÏÔÖøÏµ÷£¨Í¼4A-C£©£¬£¬»ùÓÚ´Ë£¬£¬Ñо¿Ö°Ô±½øÒ»²½½«EphA7×÷Ϊ¼ÓÈëAsh1l½éµ¼µÄÍ»´¥ÐÞ¼ôÀú³ÌµÄÖ÷Òª»ùÒòÖ®Ò»¾ÙÐÐÁËÑо¿¡£¡£¡£¡£¡£
EphÊÜÌå¼°ÆäÅäÌå Ephrin ͳ³ÆÎªEph¼Ò×åÂѰף¬£¬ÊÇÂѰ×ÀÒ°±Ëἤø¼Ò×åÖеÄ×î´ó³ÉÔ±¡£¡£¡£¡£¡£Eph/ephrinÂѰ××÷Ϊϸ°ûÍâò·Ö×Ó£¬£¬¼ÓÈëµ÷ÀíÍ»´¥µÄÐγɼ°Éñ¾ÔªµÄ¿ÉËÜÐÔ£¬£¬EphA7ÊDZàÂëEphÊÜÌåÖÐ14¸öÊÜÌåÂѰ׻ùÒòÖ®Ò»£¬£¬ÔÚÆ¤ÖÊ·¢ÓýºÍÍ»´¥¹¦Ð§ÖÐʩչÖ÷Òª×÷Óᣡ£¡£¡£¡£
Ëæºó£¬£¬Ñо¿Ö°Ô±½èÖúÒôµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þÐÐΪѧ·¶Ê½£¬£¬ÔÚÌåÄÚ/ÌåÍâ¾ù·¢Ã÷Ash1l+/-СÊóÌý¾õƤ²ãÔ˶¯ÒÀÀµµÄÉñ¾ÔªÖÐEphA7±í´ïÔ¶µÍÓÚWTСÊóµÄ£¨Í¼4D-I£©£¬£¬ÌáÐÑÁËÔÚAsh1l+/-СÊóÖÐEphA7Ô˶¯ÓÕµ¼±í´ïÊÜË𡣡£¡£¡£¡£

ͼ4 Ash1lµ÷¿ØÓ×ÊóºÍ³ÉÄêСÊóÖÐEphA7µÄ±í´ï
Ash1lͨ¹ýÞ׿¹EZH2-H3K27me3À´µ÷¿ØEphA7µÄ±í´ï
½øÒ»²½£¬£¬×÷Õß̽ÌÖAsh1lÊÇÔõÑù¼ÓÈëµ÷¿ØEphA7Ô˶¯ÓÕµ¼±í´ï£¬£¬Í¨¹ýȾɫÖÊÃâÒß³ÁµíÊÖÒÕ£¨ChIP£©·¢Ã÷£¬£¬Ash1lµÄÖ±½Ó°ÐµãH3K36me2ÔÚWTºÍAsh1l+/-СÊóAUD EphA7»ùÒòλµãÖÜΧûÓÐÏÔ×Ųî±ð£¬£¬È»¶øH3K27me3Ðźţ¨×éÂѰ׼׻ù×ªÒÆÃ¸¸´ºÏÌåPRC2´ß»¯µÄÒÖÖÆÐÔ±ê¼ÇÎÔÚAsh1l+/-СÊóEphA7»ùÒòλµãÏÔÖøÔöÌí£¨Í¼5A,B£©¡£¡£¡£¡£¡£Í¬Ê±£¬£¬Ash1l+/-СÊóÖÐH3K27ac£¨Ò»¸ö»îÔ¾µÄÔöÇ¿±ê¼Ç¡£¡£¡£¡£¡£H3K27acÓëH3K27me3¹²ÏíÒ»¸öλÖ㬣¬±£´æÞ׿¹×÷Óᣡ£¡£¡£¡££©±í´ïÒ»Á¬Ï½µ£¬£¬ÓÃNaB£¨×éÂѰ×È¥ÒÒõ£»£»£»£»¯Ã¸ÒÖÖÆ¼Á£©Ô¤´¦Öóͷ£×÷ÓýµÄÉñ¾Ôª·¢Ã÷£¬£¬´Ì¼¤Ash1l+/-Éñ¾ÔªºóH3K27acÉý¸ß£¬£¬EphA7±í´ï»Ö¸´£¨Í¼5C,D£©¡£¡£¡£¡£¡£Í¬ÑùµØ£¬£¬ÐÐΪѧЧ¹ûÏÔʾ£¬£¬Ash1l+/-СÊóÖÐH3K27me3¡¢EZH2£¨PRC2¸´ºÏÌåµÄÒ»¸öÖ÷ÒªµÄ´ß»¯Ã¸£©±í´ïˮƽÏÔÖøÔöÌí£¨Í¼5E-G£©¡£¡£¡£¡£¡£Í¨¹ýUNC1999£¨EZH1/2ÒÖÖÆ¼Á£©¶Ô×÷ÓýµÄÉñ¾Ôª¾ÙÐÐÔ¤´¦Öóͷ££¬£¬·¢Ã÷Ash1l+/-¼¤»îµÄÉñ¾ÔªÖÐEphA7±í´ïÊܵ½ÒÖÖÆµÄÕ÷Ïó»ñµÃ¸ÄÉÆ£¨Í¼5I£©¡£¡£¡£¡£¡£ÉÏÊöЧ¹ûÌáÐÑÁË£¬£¬Ash1lÔÚ»îÐÔÒÀÀµµÄPRC2½éµ¼µÄת¼ÒÖÖÆÀÛ»ýÖÐʩչÞ׿¹×÷Ó㬣¬´Ó¶øÔÊÐíEphA7ÔÚ¼¤»îµÄÉñ¾ÔªÖбí´ï¡£¡£¡£¡£¡£

ͼ5 Ash1lͨ¹ýÞ׿¹EZH2-H3K27me3ĬȻÀ´µ÷¿ØEphA7µÄ±í´ï
EphA7¸ß±í´ï¿É¸ÄÉÆAsh1l+/-СÊóÍ»´¥ÐÞ¼ôÀú³ÌȱÏݺÍÐÐΪÒì³£
»ùÓÚÉÏÊöЧ¹û£¬£¬Ñо¿Ö°Ô±Ñо¿ÁËÌá¸ßEphA7ÊÜÌå»îÐÔÊÇ·ñÄܸÄÉÆAsh1lÍ»±äСÊóµÄÍ»´¥ÐÞ¼ôÀú³ÌȱÏݺÍÐÐΪÒì³£¡£¡£¡£¡£¡£Ephrin-A5ÊÇEphA7µÄ¸ßÇ׺ÍÁ¦ÅäÌ壬£¬¼ÓÈëÏÂÓÎÐźÅ[3,4]¡£¡£¡£¡£¡£×÷ÕßÔÚ×÷ÓýµÄÉñ¾ÔªºÍСÊóÌý¾õƤ²ãÖÐÓ¦ÓÃEphrin-A5¶à¾ÛÌåµÄFcÈÚºÏÂѰף¨Ephrin-A5 Fc£©Ö±½Ó´Ì¼¤EphA7»îÐÔ[5,6]£¬£¬·¢Ã÷¸ÄÉÆÁËAsh1lÍ»±äСÊóµÄÍ»´¥ÐÞ¼ôÀú³ÌºÍÐÐΪÒì³££¨Í¼6£©¡£¡£¡£¡£¡£
ͼ6 Ephrin-A5¼¤»îEphA7¸ß±í´ïAsh1l+/-СÊóÍ»´¥ÐÞ¼ôÀú³ÌȱÏݺÍÐÐΪÒì³£
½áÂÛ
±¾ÎĽèÖúת»ùÒòÄ£×ÓÊó¡¢¶àÖÖÐÐΪѧ·¶Ê½¡¢¹âÒÅ´«Ñ§ÊÖÒÕ¡¢»îÌå³ÉÏñת¼×éÆÊÎö¼°»ùÒò±¾ÌåÂÛÆÊÎöµÈ¶àÖÖÊÖÒÕÊֶΣ¬£¬Ñо¿·¢Ã÷ǰÄÔÉñ¾ÔªAsh1lµ¥±¶Ìåȱ·¦¿Éµ¼ÖÂСÊ󱬷¢ÏàͬÄÑÌâ¡¢ÖØ¸´¿Ì°åÐÐΪ¡¢Éç½»ÕϰµÈÀàËÆ×Ô±ÕÖ¢Ñù±íÐÍ£¬£¬²¢»úÖÆÉÏÆÆËðÔ˶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ôÀú³Ì£¬£¬ÕâÊÇÒÔϸ°û×ÔÖ÷ЧӦ·½·¨½éµ¼µÄ¡£¡£¡£¡£¡£½øÒ»²½Ñо¿·¢Ã÷£¬£¬Ash1l¿Éͨ¹ý½éµ¼EZH2-H3K27me3È¥ÒÖÖÆ×÷ÓÃÌá¸ßEphA7µÄ»îÐÔÒÀÀµ±í´ï£¬£¬½ø¶øÓ°ÏìÍ»´¥Ïû³ýÀú³Ì£¬£¬²¢¸ÄÉÆAsh1l+/-СÊóÇø·ÖÄÜÁ¦Õϰ¼°ÐÐΪÕϰ¡£¡£¡£¡£¡£¸ÃÑо¿ÓÐÖúÓÚÉîÈëÏàʶASDÏà¹Ø·¢²¡»úÖÆ£¬£¬ÎªÆä¸ÉÔ¤ÖÎÁÆÌṩÁËеÄ˼Ð÷¡£¡£¡£¡£¡£
×÷ÕßÏÈÈݼ°»ù½ðÐÅÏ¢
ÕýÔÚÉϿƴó¹Ü¼ªËɽÌÊÚ¿ÎÌâ×é¾ÙÐÐÏàÖúÑо¿µÄ2017¼¶²©Ê¿Ñо¿ÉúãÆÓîÔó(Ç廪´óѧ)ºÍÉϿƴóÉúÃüѧԺµÄÌïÃçÃ粩ʿΪ±¾ÎĵÄÅäºÏµÚÒ»×÷Õß¡£¡£¡£¡£¡£ÉϿƴóÉúÃüѧԺÑо¿Éú 2016¼¶³Âç÷骡¢2017¼¶¹ùÐÞÏÍ¡¢2018¼¶ÀîÃÈ¡¢2019¼¶ÖÜî¸Ò²¶Ô±¾Ñо¿×ö³öÁËÖ÷ҪТ˳¡£¡£¡£¡£¡£¹Ü¼ªËɽÌÊÚ¡¢Çൺ´óѧÁ¥ÊôÒ½ÔºÁõÊÀ¹ú½ÌÊÚºÍÇ廪´óѧÐÜΡ½ÌÊÚΪ±¾ÎĵÄÅäºÏͨѶ×÷Õߣ¬£¬Ñо¿»ñµÃÖйú¿ÆÑ§ÔºÒÅ´«·¢ÓýËùÎâÇà·åÑо¿×é¡¢ÉϺ£Àí¹¤´óѧлºìÑо¿×éµÄ¶¦Á¦´ó¾ÙÖ§³Ö¡£¡£¡£¡£¡£Ñо¿Ò²»ñµÃÁËÉϿƴóÆÝ쿽ÌÊÚ¡¢·¶á¯Áë½ÌÊÚºÍÉϺ£½»Í¨´óѧҽѧԺÐì骽ܽÌÊÚ´ó×ÚµÄÓÐÒæ×ÊÖú¡£¡£¡£¡£¡£
¸ÃÑо¿Êܵ½¿Æ¼¼Á¢Òì2030-ÖØ´óÏîÄ¿×ÊÖú£¬£¬ºÍ×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿ÒÔ¼°ÉϺ£ÊпÆÎ¯ÏîĿ֧³Ö¡£¡£¡£¡£¡£
UG»·ÇòÉúÎïÓÐÐÒÌṩʵÑéÖÐʹÓõÄAAV¡¢Âý²¡¶¾ÔØÌ壬£¬ÓÃÏÖʵÑ鶯ÖúÁ¦ÖйúÄÔ¿ÆÑ§µÄÉú³¤¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×
[1] Liu, S.G., Tian, M.M., He, F., Li, J.N., Xie, H., Liu, W.M., Zhang, Y.T., Zhang, R., Yi, M.J.,Che, F.Y., et al. (2020). Mutations in ASH1L confer susceptibility to Tourette syndrome. Mol Psychiatr 25, 476-490.
[2] Zhu, T., Liang, C., Li, D., Tian, M., Liu, S., Gao, G., and Guan, J.S. (2016). Histone methyltransferase Ash1L mediates activity-dependent repression of neurexin-1alpha. Sci Rep 6, 26597.
[3] Beuter, S., Ardi, Z., Horovitz, O., Wuchter, J., Keller, S., Saha, R., Tripathi, K., Anunu, R., Kehat, O., Kriebel, M., et al. (2016). Sci Rep 6,1451 29710.
[4] Nguyen, T.M., Arthur, A., Zannettino, A.C.W., and Gronthos, S. (2017). EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance,migration, and adhesion via Rac 1 activation. Exp Hematol 48, 72-78.
[5] Clifford, M.A., Athar, W., Leonard, C.E., Russo, A., Sampognaro, P.J., Van der Goes, M.S., Burton, D.A., Zhao, X.M., Lalchandani, R.R., Sahin, M., et al. (2014b). EphA7 signaling guides cortical dendritic development and spine maturation. P Natl Acad Sci USA 111, 4994-4999.
[6] Depaepe, V., Suarez-Gonzalez, N., Dufour, A., Passante, L., Gorski, J.A., Jones, K.R., Ledent, C., and Vanderhaeghen, P. (2005). Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 435, 1244-1250.